Tag Archives: biomarker

Mesothelioma and the Promising New Hippo Biomarker

Mesothelioma and the Promising New Hippo Biomarker

A new review in Targeted Oncology looks at a promising new Hippo biomarker in malignant pleural mesothelioma. The new biomarker is rooted in the mesothelioma molecular pathway. A molecular pathway is how molecules work together inside your body. These pathways control cell function. And they are important in developing mesothelioma treatments. Think of molecular pathways as the airport tower controller. These pathways tell mesothelioma treatments where to go and what to do in the body. If doctors can understand how pathways work, they can develop better treatments. The goal is to develop more, and more effective, mesothelioma treatments. Promising Hippo Pathway in Malignant Pleural Mesothelioma While several drugs have been approved for treating mesothelioma, there aren’t a lot. This is … Continue reading Mesothelioma and the Promising New Hippo Biomarker »

Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion

Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion

Egyptian scientists say a new biomarker is very good at identifying mesothelioma. Pleural effusions are pockets of excess fluid. They collect around the lungs of people with certain kinds of cancer and other conditions. Biomarkers in pleural effusions are proteins and other substances found in mesothelioma patients. The new study suggests that using this biomarker the right way can lead to more accurate diagnoses. The Importance of Biomarkers in Pleural Effusions Pleural mesothelioma is a rare cancer of the lung lining. It is a challenge to diagnose. The early symptoms can be as vague as cough and fatigue. But an accurate diagnosis is often the difference between life and death. As tumors grow, mesothelioma patients produce pleural effusions or ‘water … Continue reading Serum IgG4: A New Biomarker for Mesothelioma Pleural Effusion »

Identifying New MicroRNA Tumor Biomarkers for Mesothelioma

Identifying New MicroRNA Tumor Biomarker for Mesothelioma

Identifying New MicroRNA Tumor Biomarkers for Mesothelioma Italian researchers have taken an important step forwards in what amounts to a microRNA tumor biomarker for mesothelioma. Exposure to asbestos fibers causes malignant pleural mesothelioma. An early diagnosis and comprehensive health monitoring is vital for patients exposed to asbestos fibers. Researchers at the University of Catania in Italy say these two clinical issues “may be solved by the identification of specific biomarkers.” A new article in Nature Scientific Reports identifies RNA molecules could serve as a microRNA signature for mesothelioma. This “signature” could help doctors distinguish mesothelioma from other types of cancer. The Challenge of Mesothelioma Diagnosis Pleural mesothelioma is particularly hard to diagnose. The early symptoms of mesothelioma are similar to the … Continue reading Identifying New MicroRNA Tumor Biomarkers for Mesothelioma »

New Tips for Diagnosing Malignant Peritoneal Mesothelioma

New Tips for Diagnosing Malignant Peritoneal Mesothelioma

Malignant peritoneal mesothelioma is an aggressive cancer that often mimics other conditions. This can make it difficult to get a definitive diagnosis. But a new report in Pathology Case Reviews provides tips for identifying peritoneal mesothelioma. Diagnosing Malignant Peritoneal Mesothelioma Mesothelioma is usually diagnosed after a person experiencing symptoms goes to a doctor. Patients often complain of vague abdominal symptoms, such as pain, nausea, bloating, weight loss. Distinguishing peritoneal mesothelioma from other cancers is important to ensure appropriate treatment. One thing a doctor may do is perform a tissue biopsy. The doctor will remove a part of the tissue (suspected mesothelioma) for examination. A biopsy is the “gold standard” and the single most important procedure for an accurate diagnosis. Doctors … Continue reading New Tips for Diagnosing Malignant Peritoneal Mesothelioma »

Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma

novel diagnostic marker

A protein called CDLN15 could be a novel diagnostic marker for malignant pleural mesothelioma, allowing doctors to pinpoint asbestos cancer earlier and boost the odds of survival. That is the message from a recently published Japanese study.  Pleural mesothelioma is notoriously difficult to diagnose. It rarely causes any symptoms at all until it is in a late stage. When the symptoms do show up, they are easy to confuse with other illnesses. Earlier diagnosis of pleural mesothelioma depends on finding things that set it apart from other diseases. This novel diagnostic marker could serve as a red flag for this rare but deadly cancer.  CDLN15 as a Novel Diagnostic Marker CDLN15 stands for claudin-15. Claudins are a family of proteins … Continue reading Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma »

Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which

epthelioid mesothelioma and lung cancer

Researchers from Hiroshima University say they have found a nearly foolproof way to tell the difference between epithelioid mesothelioma and lung cancer.  This is critical because the prognosis can be very different between the two. They are also treated differently.  But epithelioid mesothelioma and lung cancer are similar in many ways. They cause many of the same symptoms. Even their cells look similar under the microscope. This can make it hard for doctors to deliver an accurate and timely diagnosis.  If the new findings are right, the biomarker identified by the Hiroshima researchers could be a diagnostic gamechanger.  Lung Adenocarcinoma or Pleural Mesothelioma? At first glance, epithelioid mesothelioma and lung cancer seem to be very different. Mesothelioma makes up about … Continue reading Epithelioid Mesothelioma and Lung Cancer: Biomarker Shows Which is Which »

Genetics Affect Accuracy of SMRP Test for Mesothelioma

SMRP test for mesothelioma

The SMRP test for mesothelioma is a tool doctors use to help diagnose asbestos cancer and plan treatment. But new research suggests that the test is not as useful as it could be due to genetic variability.  Slovenian doctors say a person’s genetics influence how much SMRP they produce.  Based on their research, they recommend combining the SMRP test for mesothelioma with genetic testing. Their findings suggest the combination method produces a more accurate and useful mesothelioma biomarker. What is the SMRP Test for Mesothelioma? SMRP stands for soluble mesothelin-related peptides. They are produced when proteins found in the mesothelial membranes start to break down. Malignant mesothelioma is one condition that can trigger this breakdown.  As a mesothelioma tumor grows … Continue reading Genetics Affect Accuracy of SMRP Test for Mesothelioma »

Protein Biomarker for Mesothelioma Linked to Shorter Survival

protein biomarker for mesothelioma

An international team of scientists has identified a protein biomarker for mesothelioma that appears to shorten survival. The biomarker is CD70. It belongs to the tumor necrosis factor (TNF) family of proteins. New research suggests that patients who express more of this protein biomarker for mesothelioma have faster-growing tumors that are less likely to respond to treatment. High CD70 levels have been linked with tumor aggression in some other types of cancer. This is the first time they have been linked to malignant pleural mesothelioma survival.  CD70 and Mesothelioma Prognosis Pleural mesothelioma is a highly aggressive type of tumor. It grows on the membranes around internal organs. Mesothelioma rarely responds to standard cancer treatments. People diagnosed with pleural mesothelioma are … Continue reading Protein Biomarker for Mesothelioma Linked to Shorter Survival »

Response to Chemotherapy in Mesothelioma Patients: Could This Protein Predict It?

second-line treatment option

There is new evidence that a protein called Activin A could help predict response to chemotherapy in patients with malignant pleural mesothelioma. It may also make it easier for doctors to distinguish mesothelioma from benign lung tumors. Activin A influences many cellular processes. Among other things, it plays a role in cell proliferation, immune response, metabolism, and natural cell death.  FInnish researchers say mesothelioma patients with higher levels of Activin A in their blood are more likely to suffer from cachexia. Cachexia is weakness and wasting of the body due to chronic illness. High expressors of Activin A are also less likely to have a good response to chemotherapy.  Activin A and Mesothelioma Activin A is a member of the … Continue reading Response to Chemotherapy in Mesothelioma Patients: Could This Protein Predict It? »

MicroRNA Signature for Mesothelioma Could Lead to Earlier Diagnosis

microRNA signature for mesothelioma

Australian researchers believe they have identified what amounts to a microRNA signature for mesothelioma in pleural effusion.  Pleural effusion is the name for excess lung fluid. Up to 90 percent of pleural mesothelioma patients develop a pleural effusion. Researchers at the University of Western Australia say this fluid contains a wealth of information that could improve mesothelioma diagnosis. They have recently identified a trio of RNA molecules in fluid samples that could serve as a microRNA signature for mesothelioma. This “signature” could help doctors distinguish mesothelioma from other types of cancer. The Challenge of Mesothelioma Diagnosis Pleural mesothelioma is notoriously hard to diagnose. The early symptoms of mesothelioma are similar to the symptoms of many other lung conditions. They are … Continue reading MicroRNA Signature for Mesothelioma Could Lead to Earlier Diagnosis »